GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (OTCPK:TTNPW) » Definitions » EV-to-EBITDA

Titan Pharmaceuticals (Titan Pharmaceuticals) EV-to-EBITDA : 0.00 (As of May. 21, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Titan Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Titan Pharmaceuticals's enterprise value is $0.00 Mil. Titan Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.57 Mil. Therefore, Titan Pharmaceuticals's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Titan Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

TTNPW' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105.25   Med: -1.86   Max: 19.63
Current: 0.03

During the past 13 years, the highest EV-to-EBITDA of Titan Pharmaceuticals was 19.63. The lowest was -105.25. And the median was -1.86.

TTNPW's EV-to-EBITDA is ranked better than
94.74% of 456 companies
in the Biotechnology industry
Industry Median: 10.52 vs TTNPW: 0.03

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Titan Pharmaceuticals's stock price is $0.005. Titan Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, Titan Pharmaceuticals's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Titan Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Titan Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals EV-to-EBITDA Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.65 -2.68 -0.48 -0.90 -0.04

Titan Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -1.16 0.05 -0.04 -0.06

Competitive Comparison of Titan Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Titan Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's EV-to-EBITDA falls into.



Titan Pharmaceuticals EV-to-EBITDA Calculation

Titan Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-6.572
=0.00

Titan Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Titan Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Titan Pharmaceuticals  (OTCPK:TTNPW) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Titan Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.005/0.000
=N/A

Titan Pharmaceuticals's share price for today is $0.005.
Titan Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Titan Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.